Statement of Principles concerning inflammatory bowel disease (Reasonable Hypothesis) (No. 90 of 2020)

The instrument rests on several interconnected legal-medical concepts that determine how claims will be assessed.

Reasonable hypothesis: The SoP is explicitly titled as a “Reasonable Hypothesis” instrument and sets a declarative rule: “At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting inflammatory bowel disease or death from inflammatory bowel disease with the circumstances of a person's relevant service” (s 9). That phrase signals the standard of connection used in claims assessment: the list is not a statement of causation beyond reasonable doubt; it supplies the RMA’s view as to what facts suffice to elevate the possibility of a service connection to the statutory reasonable hypothesis level.

Onset versus worsening/material contribution: The instrument divides its factors by outcome. Sections 9(1)-(11) identify factors that satisfy the reasonable hypothesis for the clinical onset of IBD. Sections 9(12)-(23) identify factors that satisfy the reasonable hypothesis for clinical worsening of IBD or material contribution/aggravation, and s 10(2) limits those latter factors to situations where the IBD was suffered or contracted before or during, but did not arise out of, relevant service.

Defined medical scope: The SoP provides a tailored definition of inflammatory bowel disease for claims purposes (s 7(2)), expressly including Crohn disease, ulcerative colitis and IBD of unspecified type, and excluding non‑autoimmune bowel inflammation (s 7(2)(c)). It also clarifies that ICD‑10‑AM codes K50 and K51 may refer to IBD but the statutory meaning for this instrument is the one given in s 7(2) (s 7(3)-(4)).

Discrete, quantitative thresholds: Many factors are expressed as specific numeric or temporal thresholds: e.g., taking a drug from Specified List 1 for at least seven days before clinical onset (s 9(1)); NSAID use on at least ten days per month for at least two continuous months with last dose within 14 days of onset (s 9(2)); immune checkpoint inhibitor within one year before onset (s 9(3)); combined oral contraceptive pill use for six continuous months, and onset within one year of cessation (s 9(4)); smoking exposure measured in pack‑years with specified post‑cessation windows (s 9(10)(a)); second‑hand smoke exposure measured in hours (5,000 hours) with timing windows (s 9(10)(b)-(c)); at least three courses of antibiotics within five years, with last course completed at least six months before Crohn onset (s 9(10)(d)); diet and activity thresholds such as inability to consume an average 10 g/day fibre for five consecutive years (s 9(10)(e)), consuming at least 100 g/day sucrose for two consecutive years (s 9(10)(f)), inability to undertake activity greater than 3 METs for five years (s 9(10)(g)), and obesity for five years within 20 years (s 9(10)(h)).

Psychosocial stressor categories and clinical psychiatric thresholds: The instrument includes trauma and chronic stress exposure as listed factors: category 1A and 1B stressors within three months before onset/worsening (s 9(6)-(7), 9(17)-(18)), category 2 stressors within 30 days (s 9(8), 9(19)), and “clinically significant” depressive or anxiety disorder for at least one year (s 9(9), 9(20)). Schedule 1 precisely defines these categories and the meaning of “clinically significant” as “sufficient to warrant ongoing management” and states that “warrant ongoing management” does not require that any actual management was received (Schedule 1, definitions).

Cross-referencing other Statements of Principles: If a factor in this SoP refers to an injury or disease that is covered by a different SoP, the factors in that other SoP apply in accordance with their terms as in force from time to time (s 11).

Death and terminal events: Death from IBD is included where death was contributed to by the person’s IBD; “terminal event” is defined in the dictionary and includes causes such as pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function (s 7(5), Schedule 1).

Specified drugs: The Dictionary distinguishes Specified List 1 and Specified List 2 (Schedule 1): List 1 includes interferons, isotretinoin and tumour necrosis factor (TNF) antagonists; List 2 includes those plus nonsteroidal anti‑inflammatory drugs (NSAIDs). The lists determine whether drug exposure supports onset (List 1) or worsening (List 2) (s 9(1), 9(12), Schedule 1).

Relationship to service: All factors must be related to the person's relevant service (s 10(1)). The instrument defines “relevant service” to include operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, warlike and non‑warlike service under the MRCA (Schedule 1, “relevant service”).

Definitions that govern measurement: Several key definitions control evidentiary measurement , “one pack‑year” (Schedule 1), “being exposed to second‑hand smoke” (Schedule 1), BMI, MET, “organ or tissue transplantation” and others , and some definitions were amended by Determination No. 94 of 2022 (per Endnote 4).

Together, these concepts convert medical and lifestyle exposures into a closed list of factual triggers that, if established and linked to service, supply the statutory minimum for a reasonable hypothesis. The SoP therefore functions as a predictable gate for claim initiation, but its details create discrete evidentiary and measurement questions for claimants and decision‑makers.

The instrument applies to claims to which section 120A of the Veterans' Entitlements Act 1986 (VEA) or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) applies (s 5). That means it affects persons lodging or defending claims under those provisions where inflammatory bowel disease or death from inflammatory bowel disease is at issue. The Schedule 1 definition of “relevant service” (Schedule 1) clarifies which types of service are within the instrument’s scope, including operational, peacekeeping, hazardous and British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA.

Claimants: Veterans, current members of the Forces, and members of peacekeeping forces who assert that IBD (Crohn disease, ulcerative colitis, or unspecified IBD) was caused by, materially contributed to by, or aggravated by relevant service will be directly affected. For onset claims the claimant must show at least one factor from s 9(1)-(11), and for worsening/material contribution claims they must show at least one factor from s 9(12)-(23) and that the disease pre‑existed or was contracted before or during service (s 10(2)).

Medical practitioners and treating clinicians: The SoP sets out measurable clinical and exposure thresholds that treating clinicians will be asked to document or opine on for claims purposes. Examples include dates and durations of drug therapy (s 9(1), 9(3), 9(12), 9(13)), precise smoking histories quantified in pack‑years (s 9(10)(a), Schedule 1), quantified second‑hand smoke exposure (5,000 hours; s 9(10)(b)-(c), Schedule 1), body mass index and obesity history (Schedule 1), diet and activity histories (s 9(10)(e)-(g)), psychiatric diagnoses and whether a condition is “clinically significant” (Schedule 1), and transplant records (s 9(5), 9(15), Schedule 1). Clinicians may be asked to sign or certify factual timelines (onset/worsening dates) and to record inability to undertake physical activity above 3 METs. The SoP’s definitions and numeric thresholds may require clinicians to supply quantified evidence beyond typical clinical notes.

Decision‑makers and assessors: The Department of Veterans’ Affairs decision‑makers or other adjudicators applying the VEA/MRCA framework will use this SoP as the RMA’s view of what facts satisfy the reasonable hypothesis threshold. They are required to treat factors in other SoPs in accordance with those SoPs when overlap occurs (s 11). The SoP thus affects the evidentiary assessment process and the framing of medical questions referred for opinion.

Service record and administrative personnel: Evidence of exposure during service , whether drug administration records, operational incident reports proving exposure to stressors, records of deployment environments, or medical evacuation/transplant documentation , will be relevant. Personnel responsible for collating service records will need to identify and supply records that correspond to the SoP’s factors and to the defined temporal windows.

Family members and witnesses: For factors that require quantification of exposures that occurred in domestic or shared environments (e.g., second‑hand smoke hours, caregiving responsibilities), witness statements, contemporaneous logs and affidavits from family or co‑habitants may be of central evidential value.

Other regulated persons and agencies: Because the SoP refers to exposures such as organ or tissue transplantation, and to “inability to obtain appropriate clinical management” (s 9(23)), hospitals, transplant registries, and health service administrators may be drawn into claims for documentary evidence of waitlists, refusals, geographic access problems, or other barriers to care.

In sum, the instrument affects claimants (service personnel and veterans), the clinicians who document exposures and diagnoses, decision‑makers who apply the SoP at the reasonable hypothesis stage, and administrative record‑keepers whose records substantiate the enumerated thresholds. The instrument’s detailed numeric and temporal criteria also shape what evidence each of those actors will need to produce or locate for a claim to pass the reasonable hypothesis threshold.

This SoP is not a statute creating criminal offences or administrative duties in the abstract; rather, it specifies the factors that constitute the RMA’s view of the minimum evidence to raise a reasonable hypothesis that IBD (or death from IBD) is connected to relevant service. Nevertheless, it creates practical duties and rights within the VEA/MRCA claims process.

Duties of claimants (practical/evidential): A claimant seeking to establish a reasonable hypothesis must adduce evidence that at least one of the listed factors existed in the requisite form and that it related to the person’s relevant service (s 9, s 10(1)). This translates to an evidential duty to provide, or authorise disclosure of, medical records showing drug exposures and their dates (s 9(1), 9(3), 9(12), 9(13)), prescription and pharmacy records for contraceptive pill use (s 9(4), 9(14)), service medical records for exposures during service, surgical/transplantation records (s 9(5), 9(15)), psychiatric records or specialist reports establishing a “clinically significant” anxiety or depressive disorder for at least one year (s 9(9), 9(20), Schedule 1), and documentation quantifying smoking (pack‑years) and second‑hand smoke exposure (s 9(10)(a)-(c), Schedule 1). For diet, physical activity and obesity factors, claimants must supply quantified nutrition, activity and BMI histories corresponding to the periods required by the SoP (s 9(10)(e)-(h)).

Duty to show relationship to service: The SoP requires that any factor asserted “must be related to the relevant service rendered by the person” (s 10(1)). Thus claimants have the practical duty to link an enumerated exposure to their relevant service: the SoP does not itself determine relationship; it prescribes what exposures raise the reasonable hypothesis if they are related to the service.

Rights of claimants: If a claimant adduces established evidence of at least one listed factor and links it to relevant service, the claimant has, insofar as the VEA/MRCA framework requires, the right to have the application proceed beyond the reasonable hypothesis stage. The SoP supplies the RMA’s view; it functions as the evidentiary trigger that allows the claim to be considered further under the compensation framework (s 9).

Duties of medical experts and treating clinicians: Clinicians providing opinions or medical reports for claimants or for decision‑makers will be required to address the specific thresholds the SoP sets. That includes ascertaining and recording dates, durations, modal details of drug exposure, quantified tobacco use, hours of second‑hand smoke exposure, BMI history, metabolic equivalents for activity, and whether psychiatric conditions were “clinically significant” (Schedule 1). The SoP’s note that “warranting ongoing management does not require that any actual management was received or given” (Schedule 1, “clinically significant”) imposes a duty on clinicians to state whether a condition met that threshold even if no treatment was provided.

Duties of decision‑makers: Decision‑makers applying the VEA/MRCA must treat the RMA’s formulation as the minimum factual basis for a reasonable hypothesis (s 9). Where a listed factor refers to a disease or injury covered by another SoP, decision‑makers must apply those other SoP factors as in force (s 11). The SoP thus constrains the factual gates decision‑makers use at an early assessment stage.

Rights and duties concerning cross-reference: Section 11 gives effect to the right of the RMA to treat interconnected medical conditions consistently: if a factor in this SoP refers to an injury or disease covered by another SoP, the other SoP’s factors “apply in accordance with the terms” of that other SoP (s 11). That means decision‑makers must cross‑refer and apply the other SoP as currently in force.

Administrative duties: The instrument imposes a requirement on administrators to understand and apply the defined measurement units such as pack‑year, MET, BMI, and the various stressor categories in Schedule 1. For example, measuring “one pack‑year” is precisely defined (Schedule 1), and the 5,000 hour exposure requirement for second‑hand smoke is also defined.

Limitations and exclusions: The SoP excludes non‑autoimmune bowel inflammation from the definition of IBD (s 7(2)(c)). It further limits application of the worsening/material contribution factors to cases where the IBD was suffered or contracted before or during (but did not arise out of) relevant service (s 10(2)). These are legal constraints that limit the effect of certain factors.

No criminal penalties in the SoP itself: The instrument contains no offences, pecuniary penalties or standards of professional conduct beyond those found in other statutes; its effects are evidentiary and administrative within the VEA/MRCA claims processes (entire instrument).

In sum, the instrument imposes practical evidential duties on claimants and clinicians to document discrete exposures and timelines, mandates that decision‑makers apply the RMA’s view as the threshold for a reasonable hypothesis, and gives effect to cross‑SoP consistency, while not creating independent criminal or civil sanctions.

The Statement of Principles instrument itself does not create criminal penalties, civil fines, or specific enforcement mechanisms in its text. It is an evidentiary and administrative instrument, made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s 3), designed to inform decision‑making under the VEA and MRCA by specifying the RMA’s view of the factors that establish a reasonable hypothesis linking inflammatory bowel disease to relevant service (s 8, s 9). The SoP therefore functions as an evidentiary tool, not a penal code.

Operational enforcement occurs through the existing VEA/MRCA administrative and adjudicative frameworks rather than through sanctions contained in the SoP. That means:

• Decision‑makers applying the VEA/MRCA will use the SoP to determine whether a reasonable hypothesis exists and whether a claim should proceed to further medical assessment, entitlement decision or referral (s 5 and s 9). The SoP thus affects administrative outcomes (acceptance, further investigation, or rejection of claims), which in turn determine access to statutory entitlements established under the VEA/MRCA, but any denial of entitlement will be under those Acts and their appeal mechanisms, not by the SoP itself.

• The SoP may require decision‑makers to obtain or rely on medical reports, service records or other evidence to determine whether the claimant has satisfied the enumerated thresholds and whether the factor is related to relevant service (s 10(1)). The SoP does not itself specify the process for obtaining that evidence; that process is governed by the VEA/MRCA and associated administrative practice.

• Where a factor refers to an injury or disease covered by another SoP, s 11 requires application of the other SoP as in force, which imports the enforcement and application mechanisms attached to those other SoPs.

Because there are no penalties specified in the instrument, enforcement mechanisms are implicit and flow through to the VEA/MRCA processes: administrative decisions, entitlement grants or rejections, requests for further evidence, medical panels, and internal or statutory appeal rights under those Acts. The SoP’s function is therefore normative and procedural within the claims context rather than punitive.

Practically, the absence of penalties in the instrument nevertheless creates compliance costs and adverse consequences for unsuccessful claimants. If a claimant cannot demonstrate at least one listed factor linked to relevant service, the claim will likely fail to meet the reasonable hypothesis threshold, affecting the claimant’s rights to proceed under the VEA/MRCA. That effect is the operational enforcement impact of the SoP.

Finally, the instrument’s precise numeric and temporal thresholds (for example, 5,000 hours of second‑hand smoke exposure, one pack‑year definitions and cessation windows) create evidentiary hurdles. Failure to present documentary or credible corroborative evidence on those points may result in administrative rejection or the need for further investigation; any dispute about such refusals will be entertained according to the appeal routes in the VEA/MRCA framework rather than by penalties in the SoP itself.

Primary statutory context: The SoP is made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s 3) and applies to claims to which s 120A of the VEA or s 338 of the Military Rehabilitation and Compensation Act 2004 applies (s 5). That situates the SoP within the VEA/MRCA entitlement and claims framework. It is an instrument of the Repatriation Medical Authority and thereby feeds into the statutory tests used to assess service connection under those Acts.

Interaction with other Statements of Principles: Section 11 explicitly addresses cross‑SoP interaction. If a factor in this SoP refers to an injury or disease that is the subject of another SoP determined under subsection 196B(2) of the VEA, then the factors in that other SoP “apply in accordance with the terms of that Statement of Principles as in force from time to time” (s 11). That is a direct legislative instruction to cross‑apply the RMA’s separate determinations where overlap occurs. In practice this requires decision‑makers to harmonise multiple SoPs and apply the operative provisions of the other SoP in relation to the referenced disease or injury.

ICD‑10‑AM coding: Section 7(3)-(4) recognises ICD‑10‑AM codes (K50 and K51) as labels for IBD but declares that the statutory meaning of IBD for the purposes of the SoP is the definition in s 7(2). The instrument therefore displaces reliance on diagnostic code alone; it gives primacy to the statutory definition over the ICD code. The instrument cites the specific edition and effective date of the ICD‑10‑AM used (Tenth Edition, effective date 1 July 2017) and identifies the copyright holder (Independent Hospital Pricing Authority) (s 7(4)). This cross‑reference both ties the instrument to clinical coding practice and clarifies that coding is subordinate to the SoP’s textual definition.

Evidence and medical law: The SoP requires medical evidence of exposures, diagnoses and temporal relationships. That evidence will be assessed in claims adjudication under the VEA/MRCA. The SoP’s definitions and thresholds intersect with the evidentiary rules and procedures of those Acts. For example, the definition of “clinically significant” (Schedule 1) makes it possible to establish the psychiatric factor even where no actual management was provided, which interacts with evidentiary standards for medical diagnosis and treatment records.

Privacy and record disclosure statutes: While the SoP does not itself address privacy, application of its factors will typically require disclosure of medical, service and other records. The processes for obtaining and releasing those records will be governed by privacy legislation and the disclosure powers and constraints within the VEA/MRCA administrative frameworks.

Administrative law (judicial review): Decisions informed by the SoP (e.g., that a reasonable hypothesis was or was not established) will be decisions amenable to the administrative law framework applicable to statutory decision‑making under the VEA/MRCA. The SoP’s status as the RMA’s view will be a relevant consideration in judicial review or merits review contexts, although the instrument itself does not change the substantive rights under other statutes. Any reviewable error, failure to apply s 11 cross‑SoP rules, or misapplication of the SoP’s thresholds would be addressed in the usual administrative law fora; the SoP itself contains no special review mechanism.

Interaction with clinical regulation and professional obligations: Clinicians who provide opinions informed by the SoP must adhere to their professional regulatory duties when preparing reports (e.g., truthfulness, competence). The SoP’s precise numerical thresholds may require clinicians to produce quantified clinical history and opinions; failing to do so could affect the weight of their evidence in adjudication.

Amendments and subsequent instruments: The instrument is subject to later amendments and other SoPs. Endnotes record the legislation history, including an amendment determination in 2022 that revised the definition of one pack‑year (Endnotes 3 and 4). Section 11 explicitly contemplates that other SoPs may be “in force from time to time,” meaning that changes to other SoPs will affect how this SoP operates vis‑à‑vis referenced injuries or diseases.

In short, the SoP operates within and interacts with the VEA/MRCA claims machinery, other RMA SoPs, clinical coding practice (ICD‑10‑AM), administrative and privacy law frameworks, and professional regulatory environments. It does not stand alone; its operational effect depends on how it is applied under the VEA/MRCA and how related SoPs and administrative procedures are interpreted and implemented.

The compilation document contains an explicit amendment and legislation history in its endnotes. The Statement of Principles concerning inflammatory bowel disease (No. 90 of 2020) was registered on 2 November 2020 and commenced on 30 November 2020 (Endnote 3). A subsequent amending instrument, titled Veterans' Entitlements (Statements of Principles,definition of "one pack-year") Amendment Determination 2022 (No. 94 of 2022), was registered 26 August 2022 and commenced on 19 September 2022; the compilation date shown is 19 September 2022 (Endnote 3). Endnote 4 records the provision‑level amendment history and indicates that subsection notes and Schedule 1 definitions concerning “one pack‑year” were revised by Determination No. 94 of 2022 (Endnote 4, table).

The endnotes explain that this compilation shows the text as amended and in force on 19 September 2022, and that where amendments are not yet commenced they are indicated in the endnotes (compilation details). The face of the instrument includes a note that the amendment in 2022 affects the definition of “one pack‑year” and its related notes in subsection 9(10)(a) and 9(21)(a) as well as the Schedule 1 definition , the amending instrument is identified in the front matter and in Endnotes 3 and 4.

No further amendments are recorded in the supplied compilation beyond those two determinations (No. 90 of 2020 and No. 94 of 2022). The compilation includes the typical legislative compilation material: information about uncommenced amendments, modifications, self‑repealing provisions and references to the Legislation Register (front matter). The endnotes also set out an abbreviation key and outline the way misdescribed amendments are handled (Endnotes).

Practical consequence of the 2022 amendment: The 2022 Amendment Determination relates to the technical definition of “one pack‑year.” Given that multiple provisions in the SoP rely on pack‑year quantification (notably s 9(10)(a) and s 9(21)(a) for Crohn disease and its worsening), the amendment affects how smoking exposure is to be measured and therefore affects evidentiary thresholds for those items. The compilation does not include the pre‑amendment text side‑by‑side; it shows the revised definition as in force on 19 September 2022.

No other amending laws are referenced in the endnotes beyond the two items recorded in the legislation history table. The compilation notes that if the compiled law is modified by another law the compilation operates as modified but that such modifications do not amend the text and will not be shown in the compilation unless expressly incorporated (front matter notes).

For users relying on this SoP, the endnotes and the Legislation Register entry should be consulted to ascertain whether any further amendments or uncommenced amendments exist after the compilation date. The instrument itself, through s 11 and its references to other SoPs “as in force from time to time”, contemplates that its operation will be affected by future RMA determinations and amendments to other SoPs.

The compilation document supplied contains no case law, judicial decisions, or references to litigation arising under or concerning this Statement of Principles. The instrument’s endnotes record only the administrative legislation history and amendment determinations (Endnotes 3 and 4). There are no named cases or recorded judicial reviews in the text provided.

Because the SoP is an administrative instrument that guides claims under the VEA and MRCA, disputes about its application could, in practice, be subject to internal review, merits review, or judicial review under the Administrative Decisions (Judicial Review) Act or relevant administrative law provisions of the VEA/MRCA. However, the compilation text does not contain any examples of such litigation, nor does it cite any cases that have interpreted or applied this particular SoP.

If litigation exists outside of this compilation date, it is not reflected in the supplied document. For any litigation history beyond the compilation date, users should consult legal databases, the Tribunals (e.g. Veterans' Review Board) decisions, and court records to identify any administrative or judicial decisions that address the interpretation of the SoP’s factors, the measurement of pack‑years or second‑hand smoke hours, the meaning of “related to relevant service”, or disputes over onset versus worsening. The instrument itself contains no litigation history to cite.

The instrument contains numerous specific thresholds, temporal windows and definitional peculiarities that can have material evidentiary consequences. The following points are drawn from the text and identify common operational pitfalls.

1. “Related to the relevant service” is required for every factor (s 10(1)). The SoP lists factors that, if present, raise a reasonable hypothesis, but the legal connection to service must still be shown. The SoP does not itself declare factors to be service‑connected without that relationship.

2. Two distinct evidentiary regimes: onset (s 9(1)-(11)) and worsening/material contribution (s 9(12)-(23)). Section 10(2) restricts the latter to situations where the IBD was suffered or contracted before or during, but did not arise out of, the person’s service. Claimants and clinicians must be careful to identify which regime applies.

3. Numerical and temporal thresholds are precise and sometimes unusual:

   • Drugs: Specified List 1 drugs for onset require at least seven days of taking before clinical onset (s 9(1)); List 2 drugs for worsening require the same seven‑day minimum (s 9(12)). The lists are in the Schedule (interferons, isotretinoin, TNF antagonists; List 2 adds NSAIDs) (Schedule 1).
   • NSAIDs: For onset, the threshold is taking an NSAID on at least ten days per month for a continuous period of at least two months, with the last dose within 14 days of clinical onset (s 9(2)). That level of detail implies both frequency and recency requirements that must be documented.
   • Immune checkpoint inhibitors: exposure within one year of onset/worsening suffices (s 9(3), 9(13)).
   • Contraceptives: combined oral contraceptives require six continuous months and, if ceased, onset/worsening within one year of cessation (s 9(4), 9(14)).
   • Second‑hand smoke: requires 5,000 hours exposure with first exposure commencing at least one year before onset/worsening, and, if exposure ceased, onset/worsening within four years of last exposure (s 9(10)(b)-(c), 9(21)(b)-(c)). Proving 5,000 hours is likely to be difficult in most factual circumstances.
   • Pack‑year measurement: the definition of “one pack‑year” was amended in 2022 and is now precisely defined (Schedule 1 with Endnote 4). Users must apply the post‑2022 definition.

4. “Clinically significant” psychiatric disorder is defined to require sufficiency to warrant ongoing management but expressly does not require that management actually occurred (Schedule 1). This lowers the evidentiary bar for psychiatric factors but requires a diagnosis or credible documentation that the condition met that threshold.

5. “Inability to obtain appropriate clinical management” as a factor for worsening (s 9(23)) is potentially broad and will raise questions about what counts as “appropriate” and what documentary evidence is needed (e.g., waitlists, refusal letters, lack of local services). The SoP supplies no further criteria; this is an evidentiary grey area likely to require administrative guidance.

6. Measurement units that are atypical in clinical practice:

   • METs (s 9(10)(g), 9(21)(d), Schedule 1) and 3 METs as a cut‑off require clinicians to express functional capacity in metabolic equivalents, which may not routinely appear in medical records.
   • Dietary thresholds (average 10 grams fibre per day for five consecutive years, 100 g/day sucrose for two consecutive years) require historical dietary quantification that may be absent from typical clinical notes.

7. Eyewitness and corpse definitions: exposure via media is excluded from “eyewitness” (Schedule 1). “Corpse” excludes closed body bags or viewing a body in an open‑casket coffin , the detailed definitions affect whether traumatic exposures qualify as category 1B stressors.

8. Distinction between clinical onset and clinical worsening: The SoP uses both terms but does not define “clinical onset” or “clinical worsening” within its text. That can create disputes about the dates that trigger the temporal windows for many factors (e.g., last dose within 14 days of clinical onset in s 9(2)). Claimants should ensure that onset/worsening dates are clearly recorded by clinicians.

9. Cross‑SoP dependence (s 11): If a factor refers to another illness covered by a different SoP, that other SoP applies “as in force from time to time.” The interplay can therefore change over time and require updated cross‑checks.

10. Death: Death from IBD is included where IBD contributed to the terminal event (s 7(5)), but users must show that the death was contributed to by IBD rather than solely by an alternative terminal disease or event; the terminal causes listed in the dictionary (pneumonia, respiratory failure, cardiac arrest, etc.) may be proximate causes and require medical linkage to IBD.

11. Documentary burdens and plausibility: Some thresholds (5,000 hours second‑hand smoke; 5 years obesity within 20 years; 5 consecutive years of <10 g fibre per day) impose retrospective quantification that often lacks contemporaneous records. Reliance on credible witness statements, employment records (e.g., environments with smoking), or lifestyle histories will be necessary and may be contested.

12. No penalty for failure to meet thresholds in the instrument itself: failure to meet a listed factor will not produce statutory penalty but will cause the claim to fail to satisfy the reasonable hypothesis threshold, with consequent impacts on entitlement claims under the VEA/MRCA.

Practitioners and claimants should therefore pay careful attention to the precise wording of each factor, the temporal windows, and the defined measurement units when preparing or assessing claims. Missing or poorly quantified evidence on these specific items is a frequent operational pitfall.

This section sets out concrete steps and documentary priorities for claimants, clinicians, and administrators to demonstrate whether a reasonable hypothesis exists under this SoP.

1. Identify which SoP regime applies (onset or worsening)

   • Determine whether the claim alleges clinical onset of IBD, clinical worsening, or death contributed to by IBD. For onset, gather evidence relevant to s 9(1)-(11); for worsening/material contribution, gather evidence relevant to s 9(12)-(23) and confirm that the IBD was suffered or contracted before or during service and did not arise out of service (s 10(2)).

2. Establish the relevant service relationship

   • Obtain service records that document the nature and dates of relevant service (Schedule 1 “relevant service” definitions) and any in‑service exposures or incidents that link the factor to the service period (s 10(1)). Where factors occurred outside service (for example, exposures before service), be prepared to show how those exposures relate to the service claim being advanced.

3. Document clinical onset and clinical worsening dates

   • Secure contemporaneous medical evidence that records the date(s) of clinical onset and any documented worsening. Clinician notes, hospital admission records, endoscopy reports, specialist letters and diagnostic codes should be obtained. Because many thresholds are tied to dates (e.g., last dose within 14 days of onset for NSAIDs, immune checkpoint inhibitors within one year), precise dates matter.

4. Medical records and prescriber/pharmacy records for drug exposures

   • For any drug‑related factor (s 9(1), 9(3), 9(12), 9(13)), obtain prescription records, pharmacy dispensing history, hospital medication charts and specialist clinic letters that show drug name, dates, dosage and duration. For List 1 drugs (interferons, isotretinoin, TNF antagonists) and List 2 drugs (those plus NSAIDs), demonstrate the seven‑day minimum exposure and the timing relative to clinical onset/worsening.

5. NSAID-specific evidence

   • For s 9(2), document frequency of NSAID usage: at least ten days per month for two continuous months with the final dose within 14 days of clinical onset. Pharmacy dispensing records and contemporaneous entries in general practitioner charts are principal evidence.

6. Smoking and second‑hand smoke quantification

   • For pack‑year calculations, collect smoking histories that can be expressed in cigarettes per day and years smoked; apply the Schedule 1 definition of “one pack‑year” and the amended 2022 text. For second‑hand smoke, collate workplace records, living arrangements, employment histories and witness statements to support a claim of 5,000 hours exposure and timing (first exposure at least one year before onset; if exposure ceased, onset within four years of last exposure). Where precise hour counts are not available, use credible contemporaneous documents and sworn statements to create a reasonable estimate, while acknowledging the evidentiary difficulty.

7. Antibiotics, diet, activity, and obesity evidence (Crohn-specific)

   • For s 9(10)(d)-(h): obtain records showing courses of antibiotics (dates and duration), dietetic notes or credible dietary histories to substantiate fibre and sucrose consumption thresholds (10 g/day fibre for five consecutive years; 100 g/day sucrose for two consecutive years), physical activity records or occupational/functional assessments addressing inability to undertake activities greater than 3 METs for five years, and BMI records establishing obesity (BMI ≥ 30) for the requisite five‑year period within the last 20 years. Where clinical records are sparse, contemporaneous employment records, sporting or activity limitations documented by clinicians, and self‑reported but corroborated histories will be important.

8. Psychological and stressor evidence

   • For stressors and psychiatric conditions (s 9(6)-(9), s 9(17)-(20)): obtain psychiatric or GP records documenting diagnosis and management, evidence of the duration of clinically significant depressive or anxiety disorder (at least one year, Schedule 1), and documentation of traumatic or chronic stress exposure matching category 1A, 1B or 2 stressor definitions in Schedule 1. For eyewitness or corpse exposure, supply service incident reports, witness statements or unit reports. For category 2 stressors (chronic negative life events), supply contemporaneous records (e.g., caregiver documents, employer records, legal proceedings, tenancy or bankruptcy filings) that show chronic stressors and their timelines.

9. Transplantation and infection records

   • For organ or tissue transplantation factors (s 9(5), 9(15)), obtain surgical records, transplant registries, and discharge summaries (excluding corneal transplants). For bowel infection as a factor in clinical worsening (s 9(16)), secure microbiology, hospital admission and treatment records showing timing within 30 days before worsening.

10. Contraceptive history and cessation timing

    • For combined oral contraceptive pill factors (s 9(4), 9(14)), obtain prescription records, GP notes and specialist contraception counselling records showing at least six continuous months of use and any cessation dates (if cessation, onset/worsening within one year).

11. Evidence of inability to obtain appropriate clinical management (s 9(23))

    • Document waitlists, referral denials, geographic access problems, hospital correspondence, or other proof that appropriate care was not available. Provide timelines showing how the lack of appropriate management preceded and related to clinical worsening.

12. Functional capacity and METs

    • For factors referencing METs (s 9(10)(g), 9(21)(d)), clinicians should supply functional capacity assessments, exercise testing results if available, or expert opinion converting observed limitations into MET equivalents. Where objective testing is absent, reasoned clinical assessment explaining the basis for MET conclusions will assist.

13. Cross-referencing other SoPs

    • If any factor refers to another SoP‑covered disease, identify and obtain the relevant SoP and any evidence required under that instrument (s 11).

14. Prepare concise evidence maps for adjudicators

    • Assemble a schedule showing each asserted factor, the statutory subsection relied upon, precisely which documents prove each element (dates, durations, numeric quantities), and how the factor is related to the claimant’s relevant service. Explicitly address how the factual material meets the SoP thresholds.

15. Expert reports: structure and content

    • Instruct medical experts to address the SoP factors expressly: confirm onset/worsening dates, document dose/duration/date for medicines, quantify smoking and second‑hand exposures per Schedule 1 definitions, state whether psychiatric conditions were “clinically significant”, comment on BMI history and METs as required, and opine on whether the factor is related to the relevant service. Experts should be asked to explain any inference from incomplete records and to identify where assumptions are made.

16. Anticipate and remedy evidentiary gaps

    • Where precise measures (e.g., 5,000 hours of second‑hand smoke) cannot be documented, provide corroborative evidence (employment records showing prolonged indoor exposure, contemporaneous statements from co‑workers or family members, housing records). For nutritional thresholds, dietitian assessments and prior clinic notes with weight trajectories can be persuasive.

17. Administrative follow-up

    • Expect decision‑makers to request further documentation; respond promptly with the schedule of evidence and targeted expert commentary. Use the SoP’s definitions to frame requests for records from hospitals, pharmacies and service archives.

18. Keep an audit trail of submissions and records

    • Maintain a clear evidentiary chain, including authorisations for release of medical records, copies of service medical reports, pharmacy histories and signed witness statements. Given the SoP’s precise thresholds, missing documents are frequently decisive.

19. Legal and appeal planning

    • If a decision denies that a reasonable hypothesis has been raised, identify which discrete element was found missing, whether it was the relationship to relevant service or failure to meet a threshold, and prepare to address that deficiency on internal or external review with targeted evidence or updated expert opinion.

In short, compliance requires targeted, quantified evidence tailored to the SoP’s discrete criteria. Preparing claims with precise dates, quantified exposures and explicit linkages to relevant service, supported by clinicians instructed to address the SoP’s thresholds, will materially increase the chance that the claim will meet the reasonable hypothesis threshold set out in s 9 and s 10.